Synthetic cannabinoid withdrawal: A new demand on detoxification services

Drug and Alcohol Review

Volumn 34, Issue 2, 2015, Pages 147-153

  Macfarlane, Vicki ^a   Christie, Grant ^a  

^a CADS Central   (New Zealand)

Author keywords

Cannabis; Harm reduction; Substance related disorder; Substance withdrawal syndrome; Synthetic cannabinoid

Indexed keywords

CANNABINOID;

ADOLESCENT; ADULT; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH SERVICE; HUMAN; MALE; MARIJUANA ABUSE; MIDDLE AGED; NEW ZEALAND; RETROSPECTIVE STUDY; SUBSTANCE WITHDRAWAL SYNDROME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; CANNABINOIDS; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; NEW ZEALAND; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84924759841     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12225     Document Type: Article

References (36)

1. European Monitoring Centre for Drugs and Drug Addiction. Thematic paper-Understanding the 'Spice' phenomenon. Luxembourg: EMCDDA, 2009.
2. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010;197:157-162.
3. Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013;32:141-146.
4. Forester MB. Adolescent synthetic cannabinoids exposures reported to Texas poison centres. Paediatr Emerg Care 2012;28:985-989.
5. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis is a large global sample. Drug Alcohol Depend 2013;131:106-111.
6. Cohen J, Morrison S, Greenberg J, Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Paediatrics 2012;129:1064-1067.
7. Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010;118:309-310.
8. Schneir AB, Cullen J, Ly BT. 'Spice' girls; synthetic cannabinoid intoxication. J Emerg Med 2011;40:296-299.
9. Banerji S, Deutsch CM, Bronstein AC. Spice ain't so nice. Clin Toxicol 2010;48:632.
10. Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013;28:390-393.
11. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011;117:152-157.
12. Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7:296-298.
13. Vandry R, Dunn KE, Fry JA, Girling ER. A survey study to characterise use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012;120:238-241.
14. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of 'Spice Gold'. Dtsch Arztebl Int 2009;106:464-467.
15. Brents LK, Prather PL. The K2/Spice phenomenon; emergence, identification, legislation and metabolic characterisation of synthetic cannabinoids in herbal incense products. Drug Metab Rev 2013;46:72-85.
16. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase 1 hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 2011;6:e21917.
17. Ministry of Health. Drug Use in New Zealand: Key Results of the 2007/08 New Zealand Alcohol and Drug Use Survey. Wellington: Ministry of Health, 2010.
18. Oakley-Browne MA, Wells EA, McGee MA. Twelve-month and lifetime health service use in Te Rau Hinengaro: the New Zealand Mental Health Survey. Aust N Z J Psychiatry 2006;40:855-864.
19. Winstock AR The Global Drug Survey 2014 Findings. 2014; Available from: http://www.globaldrugsurvey.com/facts-figures/the-global-drug-survey-2014-findings/ (accessed August 2014).
20. Ministry of Health. Regulatory Impact Statement: Psychoactive Substances Regulations. 2014; Available from: http://www.health.govt.nz/our-work/regulation-health-and-disability-system/psychoactive-substances-regulation (accessed August 2014).
21. NZ Drug Foundation. Synthetic-cannabinoids/drug-trends. 2014; Available from: https://www.drugfoundation.org.nz/synthetic-cannabinoids/drug-trends (accessed July 2014).
22. New Zealand Government. Psychoactive Substances Act 2013. http://www.legislation.govt.nz/act/public/2013/0053/latest/DLM5042921.html.
23. Statistics New Zealand. 2013 Census District Health Board Tables. Wellington: NZ Government; 2014.
24. WDHB CADS Auckland. The 2011 CADS Report. http://www.waitematadhb.govt.nz/LinkClick.aspx?fileticket=knWTaQbQ3dw%3D&tabid=300&mid=751.
25. Committee NEA. Ethical guidelines for observational studies: observational research, audits and related activities-Revised edition. Wellington: Ministry of Health; 2012.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth edn. Washington DC: American Psychiatric Association, 2000. Text Revision.
27. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale Development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011;119:123-129.
28. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br J Addict 1989;84:1353-1357.
29. European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs-Synthetic cannabinoids in Europe. EMCDDA. 2013; Available from: http://www.emcdda.europa.eu/attachements.cfm/att_212361_EN_EMCDDA_POD_2013_Synthetic (accessed July 2014).
30. Gorelick D, Kenneth H, Levin KH, etal. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend 2012;123:141-147.
31. Lingford-Hughes A, Welch S, Peters L, Nutt D. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012;26:899-952.
32. Maher AR, Maglione M, Bagley S, etal. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-1369.
33. Evidence-based Practice Center. Off-Label Use of Atypical Antipsychotics: An Update-Comparative Effectiveness Reviews No. 43. Rockville (MD): Agency for Healthcare Research and Quality (US), 2011. Contract No.: 11-EHC087-EF.
34. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J. Quantifying the clinical significance of cannabis withdrawal. PLoS ONE 2012;7:e44864.
35. Couch RA, Madhavaram H. Phenazepam and cannabinomimetics sold as herbal highs in New Zealand. Drug Test Anal 2012;4:409-414.
36. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriterion decision analysis. Lancet 2010;376:1558-1565.